{"ticker": {"uuid": "9dc15e27-e421-40df-b046-7c61d0c52a17", "symbol": "VRAX", "name": "Virax Biolabs Group Limited Ordinary Shares", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "VRAX SEC Filings - Virax Biolabs Group Ltd 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE5FSnQzYTktdUJwN0k0TjN3M2lTLUY5RV9DaEZuanhfX3VTcXJiU0VYeERqSWw1RHYtYm5SOUhFMmt5XzdFZndxUVo0cFRIajJmem5QMW5XU1pvejlQa2oxZE5xQUhzZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:39:02+00:00", "published_display": "15 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswJBVV95cUxPYVVFTnN2QjNQQ0RTS0dzVHJ2bFpZaU5ISTBrdVgyOS12dVdEX3lzb19iMG02UjRnN0M5ZDVSeERnSjZRZF9BaEdrVjV5T09YUFlDTXZOcDUtTGRYMEFiRjk4QnZlSlgwNkdvVmIxOUdVR0JqUV9GOHlxNjJHVm4zS1NqbmRCVm9YRDFSR0R6TDNjb2JXU01YbDFkcVU0cnpudGplVVYyOW5JSmdpQU84SGdOYkJEWlk5QlU3N3Jpd2ExQ0IzQlB4Q3JDMFUyUzY1emtMLV83dWVMMkxrR0stcFFKbjZiNnlCS01fVVppYjZuNDRGTXc1RWxkamRsUTExY0xfLU9tME9vRHBEcVRkLWZuN2hTZUd5blFKY3EwNkcwZzdTZ1BkQlJpOERycER2Nm1V?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T17:08:50+00:00", "published_display": "13 Jul 2026 17:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Virax Biolabs enters immune profiling product supply deal with Fosun", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPRnFhVVpOR24tVGhCSmJid25Nb3ctQ19tSklvWXZOTzZaZXVsZGZfUGoxRWtsNXh1dXhSVi1uendQZ0xQa3pDR25jS0hCLTFyV05LSVliN09qV2xMWHRjdDJGTnc4dUptWWhiTDZ6dmdrWGM3N2tmU2R6OF9VbWZqSk9LT2Vhb2xseDh3N0tOZHVqTEgyeUstNTE5a1prU2c?oc=5", "source_name": "Market source", "published_at": "2026-07-13T09:48:28+00:00", "published_display": "13 Jul 2026 09:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Raises $3.3 Million via Exercise of Investment Options and Issues New Warrants", "summary": "Virax Biolabs Group Ltd. (VRAX) raised approximately $3.3 million by allowing an investor to exercise preferred investment options for 548,000 shares at a reduced price of $6.00 per share. In exchange for this immediate cash infusion and price reduction, the company will issue ne", "url": "https://www.tipranks.com/news/company-announcements/virax-biolabs-raises-3-3-million-via-exercise-of-investment-options-and-issues-new-warrants", "source_name": "TipRanks", "published_at": "2026-07-10T23:11:03", "published_display": "10 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs (Nasdaq: VRAX) secures $3.3M and issues new equity warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPNWJ4cS1uZW9yTHB1eVU1Zm1TUHhrVW5UZ2tOdUNBeV9LZXFlN3k3QnNnTVo4THh0b3pzUXRXazllZk5VVldfdXNfanNSbE5tQmVWUDJvMVNscUMyZl9QQnRRbTlJWmlMZE04SmJUckctMW5xSXJfT19qQXZJVkdENy0zQnF2a3VkTlMybHhnbU1lbThpeUllcWxYaWl3aEVMQnZTNHZCOVNrRG1sdjR5bndpNExvRHktX1pr?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:07:40+00:00", "published_display": "10 Jul 2026 20:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwJBVV95cUxNdE1PQktGUzVHSHh1bjNEZVZmd09oWEp6X0VQdDVfQ01rVk00ZzdQSFpEN0RGaWtSaXZ4WV9xdmtZQWVfSmZQUnE3emhHSmFIcy1zNmdFYUcwVV9ZZ2hDQ2NQRDAyZnNVY016WmVzRU1aX0dpTFM0b1JhaUIzVW0zaFhfVkxYRjRmZ3UyUWxFazctSVVMRmVKSVdiaGJlTmh3NkhwQVlsRUlIekVkdjBrSUZRbjI5ZnhEdHc0MzhrTWU1SWItY2VEMkxTYVBrMVBSR01tamZidnJkSlpXcHZMSnFOX2tXelZmZllSSThsM0NaUXM5RmF4b21fQVdKeHBubGVMZHJ4OA?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-10T20:05:00+00:00", "published_display": "10 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$3.3M cash in, new Virax Biolabs warrants out at $6 a share", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPMjJITmd2YllJUTJHRUlhUms0NTh0WGl4NkVuMU1saXVSaFlXdEMyZHk2UVgtd0FQekM2ZUJuYS1uci1xS1NvSkpmRVZ5RkZoMG8yb1NveWVHSDZndnRBSWxlSUdxa2UtSVBhZmV1TkpaRWE3SUpDWFZ6ZWJvRXhlUjE3a3IwRU5nU05UUmRtVGZ5d3NqRU1qOFh0alRqMWNhSTdlTjhCMjhnbUJ0SEdtcmJCS1liQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:05:00+00:00", "published_display": "10 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Strikes Exclusive Southeast Asia Supply Deal for ImmuneSelect with Fosun Diagnostics", "summary": "Virax Biolabs' UK subsidiary has signed an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect products, granting access to six Southeast Asian markets. This deal allows for immediate purchase-order-driven sales and phased expansion, wi", "url": "https://www.tipranks.com/news/company-announcements/virax-biolabs-strikes-exclusive-southeast-asia-supply-deal-for-immuneselect-with-fosun-diagnostics", "source_name": "TipRanks", "published_at": "2026-07-10T12:11:59", "published_display": "10 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Virax Biolabs Stock Triple In One Session?", "summary": "Virax Biolabs Group Ltd. (NASDAQ: VRAX) saw its stock price triple after signing a multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product line. This agreement expands Virax Biolabs' commercial footprint into six Southeast Asian markets and i", "url": "https://www.sahmcapital.com/news/content/why-did-virax-biolabs-stock-triple-in-one-session-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-09T22:39:44", "published_display": "09 Jul 2026 22:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Stock Skyrockets 100% on Exclusive Distribution Agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNNG1PMm9xUVVwZXBDNEpBX3BBbUFvVEYtUF8yR2VnQ09pTVVSRGVaNFpXdzR6Y0IzZ1lRTWNjeWNXUFVZUDdlZXg1d0JoSDZQV21CNWVHU29DOUhBMnRpeDNJdDZ4TUhfUVVNSlVsYlpSdEFzUUZ6SlB0aEllbWI3V0loTGdPNkJUWTNhRkU2V2dGcmtnZTJiX1VIUGhMYW1o?oc=5", "source_name": "Market source", "published_at": "2026-07-09T19:39:27+00:00", "published_display": "09 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/virax-biolabs-group-limited-announces-173500573.html", "source_name": "PR Newswire", "published_at": "2026-07-09T17:35:00+00:00", "published_display": "09 Jul 2026 17:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Jumps on Fosun Diagnostics Supply Agreement", "summary": "Virax Biolabs Group Limited (VRAX) stock surged 234.6% after announcing an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product line. The deal is expected to create immediate revenue potential in six Southeast Asian markets. The ", "url": "https://www.quiverquant.com/news/Virax+Biolabs+Jumps+on+Fosun+Diagnostics+Supply+Agreement", "source_name": "Quiver Quantitative", "published_at": "2026-07-09T15:50:00", "published_display": "09 Jul 2026 15:50", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Shares Double After Exclusive Fosun Distribution Agreement (VRAX)", "summary": "", "url": "https://finance.yahoo.com/m/4522788d-6db8-3fdb-b07f-fa814e86bb45/virax-biolabs-shares-double.html", "source_name": "InvestorsHub", "published_at": "2026-07-09T14:06:41+00:00", "published_display": "09 Jul 2026 14:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs (NASDAQ: VRAX) inks multi-country ImmuneSelect supply deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQMTFMVjJuM180cGtlYTRiTnVWZDhYZmt3bGJ2aTZ1bDlqYjVsYnNMQmhpZGhXNHd1VlRZcXBNMHZVenhNU0w2cDZtczROc2R6WGlrUFRGZ2g4b3liSi1qNU1rc3dQNXpRdjdHVW55empuRkF0SkJnQ3NjTGVWNGdqVzVkcERUQ0FLZEVaUzgzbVFoS0dTLXVTTUd5TTVwOXZLRk1oeGxtb01iWjB3V1FQQlYyMWdWc1NMaFlN?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T11:34:20+00:00", "published_display": "09 Jul 2026 11:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/virax-biolabs-signs-multi-country-113000241.html", "source_name": "PR Newswire", "published_at": "2026-07-09T11:30:00+00:00", "published_display": "09 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs signs supply pact for six Southeast Asian markets", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQU1pHeXhnOVdKTnROM1g2Z2p5eVhkbGtYU0U1SDhKLXdGbFdqaE4xbEVTQXQ1ZXZ5WnRLMGRjZzJUQmRzRjA0QlItUnVXRTlsZjVVaWdzYnpKT3F6QnZQN2JDVlNTUmRwdHNNbC1VUGp3aUloWnZ1Znp3Yl8zSWdxTlBOejY4N01JT0lEVUFDTlI5QnlpRFdLTlV6YzlMV2p0dkI1c3NKVE45WTJLU2dJQjYwRURrYkFKWnM3LVRn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T11:30:00+00:00", "published_display": "09 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[20-F] Virax Biolabs Group Ltd Files Annual Report (Foreign Issuer) | VRAX SEC Filing - Form 20-F", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQRHhTQ2U1MmF0Z29zdUdtU09mTUh2V1BDQk5MUkIzUkZ1MGxVYnpYcnI4YlNjY242cXNBWnd5cTVOWEZHNDZQaTBxRHhvU19tc0xvQXI3NTl6Xy14eHVKWm44eUoyZ1VSRWQyUEQwQnJuX2NqaU1lc2prUVQ0TWROdlNkQjRSRUhQY05Na2QtMTVlaUtJcFZPZlpWNEFOeWVSV1o2OUlZbVlURG44U3NQZE9HUjVfZDBoakJuSHRnLU9NZlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Approves 1-for-25 Share Consolidation to Maintain Nasdaq Listing", "summary": "Virax Biolabs Group Ltd. (VRAX) has approved a 1-for-25 share consolidation to be effective on June 26, 2026. This move, previously approved by shareholders, aims to raise the company's share price to meet Nasdaq's minimum $1 bid-price requirement and prevent delisting. The conso", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4496/virax-biolabs-approves-1-for-25-share-consolidation-to-maintain-nasdaq-listing/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T19:42:06", "published_display": "26 Jun 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/virax-biolabs-group-limited-announces-130000517.html", "source_name": "PR Newswire", "published_at": "2026-06-24T13:00:00+00:00", "published_display": "24 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs cuts shares 25-to-1 to try to keep Nasdaq listing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZHpBcEdmQVhvU3pTczJGR1JJU0lKT01XMGRMYk9IbUdGbEtqMmhXTF9ZME83dEVaVktENk1IVTRWa0xXV0o3WExScWNQanVnUXYwZGV6djBBd0FjeXRVR0NMWHdLTUZWQk9URG9mU2VoSUVVVWRXdjNYQm1qSjFBc2s4d3lhcDJJSTlXaVBhOHJtU1RwenRVOXlRLXpiVXBBNnRnUEloOUtmVWM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Shareholders Approve Reverse Split and Amended Charter at June 12 Meeting", "summary": "Virax Biolabs (VRAX) shareholders approved a reverse share consolidation of 10-to-1 to 30-to-1 and adopted a new memorandum and articles of association at a reconvened extraordinary meeting on June 12, 2026. This decision, made with only 3.65% of voting shares present due to adjo", "url": "https://www.tipranks.com/news/company-announcements/virax-biolabs-shareholders-approve-reverse-split-and-amended-charter-at-june-12-meeting", "source_name": "TipRanks", "published_at": "2026-06-12T13:38:36", "published_display": "12 Jun 2026 13:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs (VRAX) investors approve reverse split range and new charter", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPQUlsZ19EUDhndTd0R3VkWVlMc1FCZnR5UjRMSjZ4UTVCbjJQeWhZWGVuR1MwbEJFSENxcmV1UWp2STM5R2Z0aUxrdzA3cDZVQnZiZlJ6enFxdWRmTGlaUjlOT3kwczJBdUFjYUtnRGZBN09USW00VXZWS0Y5WGRCWFpwTmNfczQ2LXhOempZTWlNTTJDakdEdjZqdVdSZlVPVHg0RmpkdW50SE5DcUhrVGlQaW9EQ00tbFhN?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Reports Strong Early Data for Long COVID Test and Prepares Larger Validation Study", "summary": "Virax Biolabs reported strong early pilot data for its ViraxImmune blood-based test for Long COVID and related post-acute infection syndromes, showing high specificity and positive predictive value. The company plans a larger 300-patient validation study starting in Q4 2026, with", "url": "https://www.tipranks.com/news/company-announcements/virax-biolabs-reports-strong-early-data-for-long-covid-test-and-prepares-larger-validation-study", "source_name": "TipRanks", "published_at": "2026-05-26T11:39:44", "published_display": "26 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Calls June 5 EGM to Approve Reverse Share Split and Charter Amendments", "summary": "Virax Biolabs Group Ltd. has called an Extraordinary General Meeting (EGM) for June 5, 2026, to vote on a proposed reverse share consolidation, charter amendments, and potential adjournment. The board unanimously recommends approval of these proposals, which aim to restructure th", "url": "https://www.theglobeandmail.com/investing/markets/stocks/VRAX/pressreleases/2105017/virax-biolabs-calls-june-5-egm-to-approve-reverse-share-split-and-charter-amendments/", "source_name": "The Globe and Mail", "published_at": "2026-05-25T04:11:00", "published_display": "25 May 2026 04:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Stock Faces a Make-or-Break Nasdaq Vote After a Wild Week", "summary": "Virax Biolabs (NASDAQ: VRAX) faces a critical Nasdaq vote on June 5 regarding a reverse share consolidation, vital for maintaining its listing as it needs to regain compliance with the exchange's $1 minimum bid rule by July 11. Despite a recent surge, the stock closed Friday at 2", "url": "https://www.bez-kabli.pl/virax-biolabs-stock-faces-a-make-or-break-nasdaq-vote-after-a-wild-week/", "source_name": "Bez Kabli", "published_at": "2026-05-24T18:04:00", "published_display": "24 May 2026 18:04", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs (NASDAQ: VRAX) seeks 10\u201330 for 1 reverse split to meet Nasdaq bid rule", "summary": "Virax Biolabs (NASDAQ: VRAX) is calling an extraordinary general meeting on June 5, 2026, to seek shareholder approval for a 10-for-1 to 30-for-1 reverse stock split. This action is necessary to regain compliance with Nasdaq's Minimum Bid Price Rule, which requires a share price ", "url": "https://www.stocktitan.net/sec-filings/VRAX/6-k-virax-biolabs-group-ltd-current-report-foreign-issuer-18cf50dded25.html", "source_name": "Stock Titan", "published_at": "2026-05-23T02:40:04", "published_display": "23 May 2026 02:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Shares Jumping Again Ahead of Nasdaq Open", "summary": "Virax Biolabs (NASDAQ: VRAX) shares surged over 53% on Monday and continued to climb in premarket trading on Tuesday, driven by a recent ownership filing and a sponsored RedChip TV appearance. Despite the rally, the thinly traded diagnostics micro-cap remains a penny stock, tradi", "url": "https://ts2.tech/en/why-virax-biolabs-stock-is-surging-again-before-nasdaq-opens/", "source_name": "TechStock\u00b2", "published_at": "2026-05-19T09:40:44", "published_display": "19 May 2026 09:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Virax Biolabs (VRAX) Stock Trending Overnight?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPcUpTMXpVdjNJYzJVcVJIaFRMRFZ3eXlwMXpOdFRZbWlNYmY3Z2ctdFdTNFhsajVGZHNSRlB2LWFuNGZXaXZiY1c5c1NwaG9RQjUxRmJ6RTF6Y29mTWVrMVFweHpWd1RQNGtrMllVU2g2YkFHczgzTmlXcW05SmYwNmlWSGR2N1o1b3Izc2czeFlzRGFrZkExX2ZyUThLR0JqRXliUGNYamFpWHM?oc=5", "source_name": "Benzinga", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs (VRAX) surges 177% as low-float momentum meets extreme short interest", "summary": "Virax Biolabs (VRAX) stock surged 177.4% due to micro-cap momentum and short-squeeze dynamics, amplified by unusually high short interest relative to its public float. Recent short interest data indicated that shares sold short significantly exceeded the public float, and a Sched", "url": "https://www.quiverquant.com/news/Virax+Biolabs+%28VRAX%29+surges+177%25+as+low-float+momentum+meets+extreme+short+interest", "source_name": "Quiver Quantitative", "published_at": "2026-05-18T15:51:00", "published_display": "18 May 2026 15:51", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Armistice Capital amends Schedule 13G, holds 1,000,239 VRAX shares (VRAX)", "summary": "Armistice Capital, LLC and Steven Boyd have filed an amendment to Schedule 13G, disclosing beneficial ownership of 1,000,239 ordinary shares of Virax Biolabs Group Limited (VRAX), representing 4.99% of the class. The shares are directly held by Armistice Capital Master Fund Ltd.,", "url": "https://www.stocktitan.net/sec-filings/VRAX/schedule-13g-a-virax-biolabs-group-ltd-amended-passive-investment-dis-b22b7a1dd20c.html", "source_name": "Stock Titan", "published_at": "2026-05-15T15:14:58", "published_display": "15 May 2026 15:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Virax Biolabs Group Limited Or Stock Short Interest Rises to 71.68%", "summary": "Short interest in Virax Biolabs Group Limited (VRAX) surged to 71.68% of the float as of April 15th, representing a significant increase from March 31st and indicating a high level of bearish sentiment. Institutional investor activity shows a mixed picture, with some funds reduci", "url": "https://www.quiverquant.com/news/Virax+Biolabs+Group+Limited+Or+Stock+Short+Interest+Rises+to+71.68%25", "source_name": "Quiver Quantitative", "published_at": "2026-04-25T13:29:00", "published_display": "25 Apr 2026 13:29", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Virax Biolabs CEO Sets Near-Term Milestones as ViraxImmune Strategy Advances and Valuation Lags", "summary": "Virax Biolabs Group Limited, an immunology-focused biotech, is concentrating its efforts on ViraxImmune, a T cell immune-profiling assay for post-acute infection syndromes. The company's CEO, James Foster, outlined near-term milestones including a key PAIS data readout and U.S. c", "url": "https://www.theglobeandmail.com/investing/markets/stocks/VRAX/pressreleases/1319662/virax-biolabs-ceo-sets-near-term-milestones-as-viraximmune-strategy-advances-and-valuation-lags/", "source_name": "The Globe and Mail", "published_at": "2026-04-19T18:10:18", "published_display": "19 Apr 2026 18:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pre-Bell Movers | VRAX Surges by 82.6%; Here Are 20 Stocks Moving Premarket (Apr/13)", "summary": "This article highlights significant pre-market stock movements on April 13th, 2026, noting that Virax Biolabs Group Ltd. Class A (VRAX.US) surged by 82.6%. It also details broader market reactions to geopolitical tensions, including a rise in WTI crude oil and drops in major tech", "url": "https://www.sahmcapital.com/news/content/pre-bell-movers-vrax-surges-by-826-here-are-20-stocks-moving-premarket-apr13-2026-04-13", "source_name": "Sahm", "published_at": "2026-04-16T17:09:17", "published_display": "16 Apr 2026 17:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxQTjExRWxEbzFFbmdDZmpqdEc3eGI1eEg3TWwzZHRLN245WWhJXzduMmpuWDIxM0JoOFV5UHRUUXZNMWFwTl9tMXBndi1HVlQzby1zNi0td1pHOU4xQjVBeFN2WmdtUG5hQ0VCODllb0hXamFvQTB1NFk5ejQ3RkRiTXJuVG9CaWhRNlhLX2dZNTNabGFXSzluQWJ5N3hYQngyenM4bmEzUXp2R0txV3VpR3NWdXk1STNOM2E3aFYyZlNtclZxTlZLRnkzaWctQXB0aGxrSk0wWGFjdloxdkFlWjBKczNlNEo1VzRqeENRT3Y4MmNxdjRSc3RBVQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Monday's Pre-Market Session", "summary": "This article lists 12 healthcare stocks that experienced significant price movements in Monday's pre-market session. It highlights both gainers, such as Virax Biolabs Group and Allogene Therapeutics, and losers, including Replimune Group and Beyond Air, detailing their stock chan", "url": "https://www.sahmcapital.com/news/content/12-health-care-stocks-moving-in-mondays-pre-market-session-2026-04-13", "source_name": "Sahm", "published_at": "2026-04-13T10:40:30", "published_display": "13 Apr 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Announces Full Exercise of Pre-Funded Warrants From $5 Million Private Placement", "summary": "Virax Biolabs Group Ltd. announced the full exercise of pre-funded warrants from a $5 million private placement initiated in December 2025. This exercise, completed by April 10, 2026, increased the company's ordinary shares outstanding to 19,923,432, converting the financing into", "url": "https://www.tipranks.com/news/company-announcements/virax-biolabs-announces-full-exercise-of-pre-funded-warrants-from-5-million-private-placement", "source_name": "TipRanks", "published_at": "2026-04-10T21:02:49", "published_display": "10 Apr 2026 21:02", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Shareholders Approve Reverse Split, New Charter and 2026 Equity Plan After Adjourned AGM", "summary": "Virax Biolabs Group Ltd. shareholders approved a reverse stock split, an updated charter, and a 2026 Equity Incentive Plan during its recently reconvened annual general meeting on March 18, 2026. These strategic moves aim to streamline the company's capital structure and support ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/VRAX/pressreleases/853217/virax-biolabs-shareholders-approve-reverse-split-new-charter-and-2026-equity-plan-after-adjourned-agm/", "source_name": "The Globe and Mail", "published_at": "2026-04-02T05:39:50", "published_display": "02 Apr 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Nelson Haight reports Virax Biolabs (VRAX) stock option awards", "summary": "Virax Biolabs Group Ltd director Nelson M. Haight has reported his initial beneficial ownership of various stock option awards. These options, granted under the company's 2023 and 2024 Equity Incentive Plans, have different exercise prices, expiration dates, and vesting schedules", "url": "https://www.stocktitan.net/sec-filings/VRAX/form-3-virax-biolabs-group-ltd-initial-statement-of-beneficial-owners-239f9460c662.html", "source_name": "Stock Titan", "published_at": "2026-03-31T19:39:38", "published_display": "31 Mar 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Behind The Jump In Virax Biolabs Stock?", "summary": "Shares of Virax Biolabs Group are soaring after its wholly-owned subsidiary, Virax Biolabs (UK) Limited, achieved ISO 13485:2016 and ISO 9001:2015 certifications for its quality management system. These certifications lay the foundation for quality-managed development activities,", "url": "https://www.sahmcapital.com/news/content/whats-behind-the-jump-in-virax-biolabs-stock-2026-03-31", "source_name": "Sahm", "published_at": "2026-03-31T18:09:55", "published_display": "31 Mar 2026 18:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Virax Biolabs (NASDAQ: VRAX) COO discloses multiple long-dated stock options", "summary": "Virax Biolabs (NASDAQ: VRAX) Chief Operating Officer, Nigel William McCracken, filed an initial Form 3, disclosing his holdings of multiple long-dated stock options. These options, granted under the company's 2023 and 2024 Equity Incentive Plans, have varying exercise prices and ", "url": "https://www.stocktitan.net/sec-filings/VRAX/form-3-virax-biolabs-group-ltd-initial-statement-of-beneficial-owners-b82cd9fa50cd.html", "source_name": "Stock Titan", "published_at": "2026-03-21T14:38:52", "published_display": "21 Mar 2026 14:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs (VRAX) director files initial insider ownership report", "summary": "Virax Biolabs Group Ltd director Miller Iain David has filed a Form 3, an initial statement of beneficial ownership, with the SEC. This filing establishes his starting equity position as an insider of the company, confirming his role as a director. The Form 3 does not indicate an", "url": "https://www.stocktitan.net/sec-filings/VRAX/form-3-virax-biolabs-group-ltd-initial-statement-of-beneficial-owners-220e96388c62.html", "source_name": "Stock Titan", "published_at": "2026-03-19T14:38:52", "published_display": "19 Mar 2026 14:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPZ3ZESTUzR0F6Ti1LVHh6SElkcGZ5ZG5oclZ0MmJuUEZ1ZmhmVWlxbE5uZDc1cm5qbFE1T0ZVSm5UUmFRX0NpZ0Rvc0RGbWZ1Q3F4bEpFdHFzOEljclplUXNSdGNKcE5nRG54MmFPUUgwS3RxWGEwRWNBR1RGdS1oZHlDeW4?oc=5", "source_name": "Market source", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "VRAX SEC Filings - Virax Biolabs Group Ltd 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE5FSnQzYTktdUJwN0k0TjN3M2lTLUY5RV9DaEZuanhfX3VTcXJiU0VYeERqSWw1RHYtYm5SOUhFMmt5XzdFZndxUVo0cFRIajJmem5QMW5XU1pvejlQa2oxZE5xQUhzZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:39:02+00:00", "published_display": "15 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswJBVV95cUxPYVVFTnN2QjNQQ0RTS0dzVHJ2bFpZaU5ISTBrdVgyOS12dVdEX3lzb19iMG02UjRnN0M5ZDVSeERnSjZRZF9BaEdrVjV5T09YUFlDTXZOcDUtTGRYMEFiRjk4QnZlSlgwNkdvVmIxOUdVR0JqUV9GOHlxNjJHVm4zS1NqbmRCVm9YRDFSR0R6TDNjb2JXU01YbDFkcVU0cnpudGplVVYyOW5JSmdpQU84SGdOYkJEWlk5QlU3N3Jpd2ExQ0IzQlB4Q3JDMFUyUzY1emtMLV83dWVMMkxrR0stcFFKbjZiNnlCS01fVVppYjZuNDRGTXc1RWxkamRsUTExY0xfLU9tME9vRHBEcVRkLWZuN2hTZUd5blFKY3EwNkcwZzdTZ1BkQlJpOERycER2Nm1V?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T17:08:50+00:00", "published_display": "13 Jul 2026 17:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs enters immune profiling product supply deal with Fosun", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPRnFhVVpOR24tVGhCSmJid25Nb3ctQ19tSklvWXZOTzZaZXVsZGZfUGoxRWtsNXh1dXhSVi1uendQZ0xQa3pDR25jS0hCLTFyV05LSVliN09qV2xMWHRjdDJGTnc4dUptWWhiTDZ6dmdrWGM3N2tmU2R6OF9VbWZqSk9LT2Vhb2xseDh3N0tOZHVqTEgyeUstNTE5a1prU2c?oc=5", "source_name": "Market source", "published_at": "2026-07-13T09:48:28+00:00", "published_display": "13 Jul 2026 09:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Raises $3.3 Million via Exercise of Investment Options and Issues New Warrants", "summary": "Virax Biolabs Group Ltd. (VRAX) raised approximately $3.3 million by allowing an investor to exercise preferred investment options for 548,000 shares at a reduced price of $6.00 per share. In exchange for this immediate cash infusion and price reduction, the company will issue ne", "url": "https://www.tipranks.com/news/company-announcements/virax-biolabs-raises-3-3-million-via-exercise-of-investment-options-and-issues-new-warrants", "source_name": "TipRanks", "published_at": "2026-07-10T23:11:03", "published_display": "10 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs (Nasdaq: VRAX) secures $3.3M and issues new equity warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPNWJ4cS1uZW9yTHB1eVU1Zm1TUHhrVW5UZ2tOdUNBeV9LZXFlN3k3QnNnTVo4THh0b3pzUXRXazllZk5VVldfdXNfanNSbE5tQmVWUDJvMVNscUMyZl9QQnRRbTlJWmlMZE04SmJUckctMW5xSXJfT19qQXZJVkdENy0zQnF2a3VkTlMybHhnbU1lbThpeUllcWxYaWl3aEVMQnZTNHZCOVNrRG1sdjR5bndpNExvRHktX1pr?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:07:40+00:00", "published_display": "10 Jul 2026 20:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwJBVV95cUxNdE1PQktGUzVHSHh1bjNEZVZmd09oWEp6X0VQdDVfQ01rVk00ZzdQSFpEN0RGaWtSaXZ4WV9xdmtZQWVfSmZQUnE3emhHSmFIcy1zNmdFYUcwVV9ZZ2hDQ2NQRDAyZnNVY016WmVzRU1aX0dpTFM0b1JhaUIzVW0zaFhfVkxYRjRmZ3UyUWxFazctSVVMRmVKSVdiaGJlTmh3NkhwQVlsRUlIekVkdjBrSUZRbjI5ZnhEdHc0MzhrTWU1SWItY2VEMkxTYVBrMVBSR01tamZidnJkSlpXcHZMSnFOX2tXelZmZllSSThsM0NaUXM5RmF4b21fQVdKeHBubGVMZHJ4OA?oc=5", "source_name": "PR Newswire", "published_at": "2026-07-10T20:05:00+00:00", "published_display": "10 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$3.3M cash in, new Virax Biolabs warrants out at $6 a share", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPMjJITmd2YllJUTJHRUlhUms0NTh0WGl4NkVuMU1saXVSaFlXdEMyZHk2UVgtd0FQekM2ZUJuYS1uci1xS1NvSkpmRVZ5RkZoMG8yb1NveWVHSDZndnRBSWxlSUdxa2UtSVBhZmV1TkpaRWE3SUpDWFZ6ZWJvRXhlUjE3a3IwRU5nU05UUmRtVGZ5d3NqRU1qOFh0alRqMWNhSTdlTjhCMjhnbUJ0SEdtcmJCS1liQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:05:00+00:00", "published_display": "10 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Strikes Exclusive Southeast Asia Supply Deal for ImmuneSelect with Fosun Diagnostics", "summary": "Virax Biolabs' UK subsidiary has signed an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect products, granting access to six Southeast Asian markets. This deal allows for immediate purchase-order-driven sales and phased expansion, wi", "url": "https://www.tipranks.com/news/company-announcements/virax-biolabs-strikes-exclusive-southeast-asia-supply-deal-for-immuneselect-with-fosun-diagnostics", "source_name": "TipRanks", "published_at": "2026-07-10T12:11:59", "published_display": "10 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Virax Biolabs Stock Triple In One Session?", "summary": "Virax Biolabs Group Ltd. (NASDAQ: VRAX) saw its stock price triple after signing a multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product line. This agreement expands Virax Biolabs' commercial footprint into six Southeast Asian markets and i", "url": "https://www.sahmcapital.com/news/content/why-did-virax-biolabs-stock-triple-in-one-session-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-09T22:39:44", "published_display": "09 Jul 2026 22:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Stock Skyrockets 100% on Exclusive Distribution Agreement", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNNG1PMm9xUVVwZXBDNEpBX3BBbUFvVEYtUF8yR2VnQ09pTVVSRGVaNFpXdzR6Y0IzZ1lRTWNjeWNXUFVZUDdlZXg1d0JoSDZQV21CNWVHU29DOUhBMnRpeDNJdDZ4TUhfUVVNSlVsYlpSdEFzUUZ6SlB0aEllbWI3V0loTGdPNkJUWTNhRkU2V2dGcmtnZTJiX1VIUGhMYW1o?oc=5", "source_name": "Market source", "published_at": "2026-07-09T19:39:27+00:00", "published_display": "09 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/virax-biolabs-group-limited-announces-173500573.html", "source_name": "PR Newswire", "published_at": "2026-07-09T17:35:00+00:00", "published_display": "09 Jul 2026 17:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Jumps on Fosun Diagnostics Supply Agreement", "summary": "Virax Biolabs Group Limited (VRAX) stock surged 234.6% after announcing an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product line. The deal is expected to create immediate revenue potential in six Southeast Asian markets. The ", "url": "https://www.quiverquant.com/news/Virax+Biolabs+Jumps+on+Fosun+Diagnostics+Supply+Agreement", "source_name": "Quiver Quantitative", "published_at": "2026-07-09T15:50:00", "published_display": "09 Jul 2026 15:50", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Shares Double After Exclusive Fosun Distribution Agreement (VRAX)", "summary": "", "url": "https://finance.yahoo.com/m/4522788d-6db8-3fdb-b07f-fa814e86bb45/virax-biolabs-shares-double.html", "source_name": "InvestorsHub", "published_at": "2026-07-09T14:06:41+00:00", "published_display": "09 Jul 2026 14:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs (NASDAQ: VRAX) inks multi-country ImmuneSelect supply deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQMTFMVjJuM180cGtlYTRiTnVWZDhYZmt3bGJ2aTZ1bDlqYjVsYnNMQmhpZGhXNHd1VlRZcXBNMHZVenhNU0w2cDZtczROc2R6WGlrUFRGZ2g4b3liSi1qNU1rc3dQNXpRdjdHVW55empuRkF0SkJnQ3NjTGVWNGdqVzVkcERUQ0FLZEVaUzgzbVFoS0dTLXVTTUd5TTVwOXZLRk1oeGxtb01iWjB3V1FQQlYyMWdWc1NMaFlN?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T11:34:20+00:00", "published_display": "09 Jul 2026 11:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/virax-biolabs-signs-multi-country-113000241.html", "source_name": "PR Newswire", "published_at": "2026-07-09T11:30:00+00:00", "published_display": "09 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs signs supply pact for six Southeast Asian markets", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQU1pHeXhnOVdKTnROM1g2Z2p5eVhkbGtYU0U1SDhKLXdGbFdqaE4xbEVTQXQ1ZXZ5WnRLMGRjZzJUQmRzRjA0QlItUnVXRTlsZjVVaWdzYnpKT3F6QnZQN2JDVlNTUmRwdHNNbC1VUGp3aUloWnZ1Znp3Yl8zSWdxTlBOejY4N01JT0lEVUFDTlI5QnlpRFdLTlV6YzlMV2p0dkI1c3NKVE45WTJLU2dJQjYwRURrYkFKWnM3LVRn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T11:30:00+00:00", "published_display": "09 Jul 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[20-F] Virax Biolabs Group Ltd Files Annual Report (Foreign Issuer) | VRAX SEC Filing - Form 20-F", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQRHhTQ2U1MmF0Z29zdUdtU09mTUh2V1BDQk5MUkIzUkZ1MGxVYnpYcnI4YlNjY242cXNBWnd5cTVOWEZHNDZQaTBxRHhvU19tc0xvQXI3NTl6Xy14eHVKWm44eUoyZ1VSRWQyUEQwQnJuX2NqaU1lc2prUVQ0TWROdlNkQjRSRUhQY05Na2QtMTVlaUtJcFZPZlpWNEFOeWVSV1o2OUlZbVlURG44U3NQZE9HUjVfZDBoakJuSHRnLU9NZlE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Approves 1-for-25 Share Consolidation to Maintain Nasdaq Listing", "summary": "Virax Biolabs Group Ltd. (VRAX) has approved a 1-for-25 share consolidation to be effective on June 26, 2026. This move, previously approved by shareholders, aims to raise the company's share price to meet Nasdaq's minimum $1 bid-price requirement and prevent delisting. The conso", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/4496/virax-biolabs-approves-1-for-25-share-consolidation-to-maintain-nasdaq-listing/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T19:42:06", "published_display": "26 Jun 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/virax-biolabs-group-limited-announces-130000517.html", "source_name": "PR Newswire", "published_at": "2026-06-24T13:00:00+00:00", "published_display": "24 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs cuts shares 25-to-1 to try to keep Nasdaq listing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZHpBcEdmQVhvU3pTczJGR1JJU0lKT01XMGRMYk9IbUdGbEtqMmhXTF9ZME83dEVaVktENk1IVTRWa0xXV0o3WExScWNQanVnUXYwZGV6djBBd0FjeXRVR0NMWHdLTUZWQk9URG9mU2VoSUVVVWRXdjNYQm1qSjFBc2s4d3lhcDJJSTlXaVBhOHJtU1RwenRVOXlRLXpiVXBBNnRnUEloOUtmVWM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Shareholders Approve Reverse Split and Amended Charter at June 12 Meeting", "summary": "Virax Biolabs (VRAX) shareholders approved a reverse share consolidation of 10-to-1 to 30-to-1 and adopted a new memorandum and articles of association at a reconvened extraordinary meeting on June 12, 2026. This decision, made with only 3.65% of voting shares present due to adjo", "url": "https://www.tipranks.com/news/company-announcements/virax-biolabs-shareholders-approve-reverse-split-and-amended-charter-at-june-12-meeting", "source_name": "TipRanks", "published_at": "2026-06-12T13:38:36", "published_display": "12 Jun 2026 13:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs (VRAX) investors approve reverse split range and new charter", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPQUlsZ19EUDhndTd0R3VkWVlMc1FCZnR5UjRMSjZ4UTVCbjJQeWhZWGVuR1MwbEJFSENxcmV1UWp2STM5R2Z0aUxrdzA3cDZVQnZiZlJ6enFxdWRmTGlaUjlOT3kwczJBdUFjYUtnRGZBN09USW00VXZWS0Y5WGRCWFpwTmNfczQ2LXhOempZTWlNTTJDakdEdjZqdVdSZlVPVHg0RmpkdW50SE5DcUhrVGlQaW9EQ00tbFhN?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Reports Strong Early Data for Long COVID Test and Prepares Larger Validation Study", "summary": "Virax Biolabs reported strong early pilot data for its ViraxImmune blood-based test for Long COVID and related post-acute infection syndromes, showing high specificity and positive predictive value. The company plans a larger 300-patient validation study starting in Q4 2026, with", "url": "https://www.tipranks.com/news/company-announcements/virax-biolabs-reports-strong-early-data-for-long-covid-test-and-prepares-larger-validation-study", "source_name": "TipRanks", "published_at": "2026-05-26T11:39:44", "published_display": "26 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Calls June 5 EGM to Approve Reverse Share Split and Charter Amendments", "summary": "Virax Biolabs Group Ltd. has called an Extraordinary General Meeting (EGM) for June 5, 2026, to vote on a proposed reverse share consolidation, charter amendments, and potential adjournment. The board unanimously recommends approval of these proposals, which aim to restructure th", "url": "https://www.theglobeandmail.com/investing/markets/stocks/VRAX/pressreleases/2105017/virax-biolabs-calls-june-5-egm-to-approve-reverse-share-split-and-charter-amendments/", "source_name": "The Globe and Mail", "published_at": "2026-05-25T04:11:00", "published_display": "25 May 2026 04:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Stock Faces a Make-or-Break Nasdaq Vote After a Wild Week", "summary": "Virax Biolabs (NASDAQ: VRAX) faces a critical Nasdaq vote on June 5 regarding a reverse share consolidation, vital for maintaining its listing as it needs to regain compliance with the exchange's $1 minimum bid rule by July 11. Despite a recent surge, the stock closed Friday at 2", "url": "https://www.bez-kabli.pl/virax-biolabs-stock-faces-a-make-or-break-nasdaq-vote-after-a-wild-week/", "source_name": "Bez Kabli", "published_at": "2026-05-24T18:04:00", "published_display": "24 May 2026 18:04", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs (NASDAQ: VRAX) seeks 10\u201330 for 1 reverse split to meet Nasdaq bid rule", "summary": "Virax Biolabs (NASDAQ: VRAX) is calling an extraordinary general meeting on June 5, 2026, to seek shareholder approval for a 10-for-1 to 30-for-1 reverse stock split. This action is necessary to regain compliance with Nasdaq's Minimum Bid Price Rule, which requires a share price ", "url": "https://www.stocktitan.net/sec-filings/VRAX/6-k-virax-biolabs-group-ltd-current-report-foreign-issuer-18cf50dded25.html", "source_name": "Stock Titan", "published_at": "2026-05-23T02:40:04", "published_display": "23 May 2026 02:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Shares Jumping Again Ahead of Nasdaq Open", "summary": "Virax Biolabs (NASDAQ: VRAX) shares surged over 53% on Monday and continued to climb in premarket trading on Tuesday, driven by a recent ownership filing and a sponsored RedChip TV appearance. Despite the rally, the thinly traded diagnostics micro-cap remains a penny stock, tradi", "url": "https://ts2.tech/en/why-virax-biolabs-stock-is-surging-again-before-nasdaq-opens/", "source_name": "TechStock\u00b2", "published_at": "2026-05-19T09:40:44", "published_display": "19 May 2026 09:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Virax Biolabs (VRAX) Stock Trending Overnight?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPcUpTMXpVdjNJYzJVcVJIaFRMRFZ3eXlwMXpOdFRZbWlNYmY3Z2ctdFdTNFhsajVGZHNSRlB2LWFuNGZXaXZiY1c5c1NwaG9RQjUxRmJ6RTF6Y29mTWVrMVFweHpWd1RQNGtrMllVU2g2YkFHczgzTmlXcW05SmYwNmlWSGR2N1o1b3Izc2czeFlzRGFrZkExX2ZyUThLR0JqRXliUGNYamFpWHM?oc=5", "source_name": "Benzinga", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs (VRAX) surges 177% as low-float momentum meets extreme short interest", "summary": "Virax Biolabs (VRAX) stock surged 177.4% due to micro-cap momentum and short-squeeze dynamics, amplified by unusually high short interest relative to its public float. Recent short interest data indicated that shares sold short significantly exceeded the public float, and a Sched", "url": "https://www.quiverquant.com/news/Virax+Biolabs+%28VRAX%29+surges+177%25+as+low-float+momentum+meets+extreme+short+interest", "source_name": "Quiver Quantitative", "published_at": "2026-05-18T15:51:00", "published_display": "18 May 2026 15:51", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Armistice Capital amends Schedule 13G, holds 1,000,239 VRAX shares (VRAX)", "summary": "Armistice Capital, LLC and Steven Boyd have filed an amendment to Schedule 13G, disclosing beneficial ownership of 1,000,239 ordinary shares of Virax Biolabs Group Limited (VRAX), representing 4.99% of the class. The shares are directly held by Armistice Capital Master Fund Ltd.,", "url": "https://www.stocktitan.net/sec-filings/VRAX/schedule-13g-a-virax-biolabs-group-ltd-amended-passive-investment-dis-b22b7a1dd20c.html", "source_name": "Stock Titan", "published_at": "2026-05-15T15:14:58", "published_display": "15 May 2026 15:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Group Limited Or Stock Short Interest Rises to 71.68%", "summary": "Short interest in Virax Biolabs Group Limited (VRAX) surged to 71.68% of the float as of April 15th, representing a significant increase from March 31st and indicating a high level of bearish sentiment. Institutional investor activity shows a mixed picture, with some funds reduci", "url": "https://www.quiverquant.com/news/Virax+Biolabs+Group+Limited+Or+Stock+Short+Interest+Rises+to+71.68%25", "source_name": "Quiver Quantitative", "published_at": "2026-04-25T13:29:00", "published_display": "25 Apr 2026 13:29", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs CEO Sets Near-Term Milestones as ViraxImmune Strategy Advances and Valuation Lags", "summary": "Virax Biolabs Group Limited, an immunology-focused biotech, is concentrating its efforts on ViraxImmune, a T cell immune-profiling assay for post-acute infection syndromes. The company's CEO, James Foster, outlined near-term milestones including a key PAIS data readout and U.S. c", "url": "https://www.theglobeandmail.com/investing/markets/stocks/VRAX/pressreleases/1319662/virax-biolabs-ceo-sets-near-term-milestones-as-viraximmune-strategy-advances-and-valuation-lags/", "source_name": "The Globe and Mail", "published_at": "2026-04-19T18:10:18", "published_display": "19 Apr 2026 18:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pre-Bell Movers | VRAX Surges by 82.6%; Here Are 20 Stocks Moving Premarket (Apr/13)", "summary": "This article highlights significant pre-market stock movements on April 13th, 2026, noting that Virax Biolabs Group Ltd. Class A (VRAX.US) surged by 82.6%. It also details broader market reactions to geopolitical tensions, including a rise in WTI crude oil and drops in major tech", "url": "https://www.sahmcapital.com/news/content/pre-bell-movers-vrax-surges-by-826-here-are-20-stocks-moving-premarket-apr13-2026-04-13", "source_name": "Sahm", "published_at": "2026-04-16T17:09:17", "published_display": "16 Apr 2026 17:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxQTjExRWxEbzFFbmdDZmpqdEc3eGI1eEg3TWwzZHRLN245WWhJXzduMmpuWDIxM0JoOFV5UHRUUXZNMWFwTl9tMXBndi1HVlQzby1zNi0td1pHOU4xQjVBeFN2WmdtUG5hQ0VCODllb0hXamFvQTB1NFk5ejQ3RkRiTXJuVG9CaWhRNlhLX2dZNTNabGFXSzluQWJ5N3hYQngyenM4bmEzUXp2R0txV3VpR3NWdXk1STNOM2E3aFYyZlNtclZxTlZLRnkzaWctQXB0aGxrSk0wWGFjdloxdkFlWjBKczNlNEo1VzRqeENRT3Y4MmNxdjRSc3RBVQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Monday's Pre-Market Session", "summary": "This article lists 12 healthcare stocks that experienced significant price movements in Monday's pre-market session. It highlights both gainers, such as Virax Biolabs Group and Allogene Therapeutics, and losers, including Replimune Group and Beyond Air, detailing their stock chan", "url": "https://www.sahmcapital.com/news/content/12-health-care-stocks-moving-in-mondays-pre-market-session-2026-04-13", "source_name": "Sahm", "published_at": "2026-04-13T10:40:30", "published_display": "13 Apr 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Announces Full Exercise of Pre-Funded Warrants From $5 Million Private Placement", "summary": "Virax Biolabs Group Ltd. announced the full exercise of pre-funded warrants from a $5 million private placement initiated in December 2025. This exercise, completed by April 10, 2026, increased the company's ordinary shares outstanding to 19,923,432, converting the financing into", "url": "https://www.tipranks.com/news/company-announcements/virax-biolabs-announces-full-exercise-of-pre-funded-warrants-from-5-million-private-placement", "source_name": "TipRanks", "published_at": "2026-04-10T21:02:49", "published_display": "10 Apr 2026 21:02", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Shareholders Approve Reverse Split, New Charter and 2026 Equity Plan After Adjourned AGM", "summary": "Virax Biolabs Group Ltd. shareholders approved a reverse stock split, an updated charter, and a 2026 Equity Incentive Plan during its recently reconvened annual general meeting on March 18, 2026. These strategic moves aim to streamline the company's capital structure and support ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/VRAX/pressreleases/853217/virax-biolabs-shareholders-approve-reverse-split-new-charter-and-2026-equity-plan-after-adjourned-agm/", "source_name": "The Globe and Mail", "published_at": "2026-04-02T05:39:50", "published_display": "02 Apr 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Nelson Haight reports Virax Biolabs (VRAX) stock option awards", "summary": "Virax Biolabs Group Ltd director Nelson M. Haight has reported his initial beneficial ownership of various stock option awards. These options, granted under the company's 2023 and 2024 Equity Incentive Plans, have different exercise prices, expiration dates, and vesting schedules", "url": "https://www.stocktitan.net/sec-filings/VRAX/form-3-virax-biolabs-group-ltd-initial-statement-of-beneficial-owners-239f9460c662.html", "source_name": "Stock Titan", "published_at": "2026-03-31T19:39:38", "published_display": "31 Mar 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Behind The Jump In Virax Biolabs Stock?", "summary": "Shares of Virax Biolabs Group are soaring after its wholly-owned subsidiary, Virax Biolabs (UK) Limited, achieved ISO 13485:2016 and ISO 9001:2015 certifications for its quality management system. These certifications lay the foundation for quality-managed development activities,", "url": "https://www.sahmcapital.com/news/content/whats-behind-the-jump-in-virax-biolabs-stock-2026-03-31", "source_name": "Sahm", "published_at": "2026-03-31T18:09:55", "published_display": "31 Mar 2026 18:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs (NASDAQ: VRAX) COO discloses multiple long-dated stock options", "summary": "Virax Biolabs (NASDAQ: VRAX) Chief Operating Officer, Nigel William McCracken, filed an initial Form 3, disclosing his holdings of multiple long-dated stock options. These options, granted under the company's 2023 and 2024 Equity Incentive Plans, have varying exercise prices and ", "url": "https://www.stocktitan.net/sec-filings/VRAX/form-3-virax-biolabs-group-ltd-initial-statement-of-beneficial-owners-b82cd9fa50cd.html", "source_name": "Stock Titan", "published_at": "2026-03-21T14:38:52", "published_display": "21 Mar 2026 14:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs (VRAX) director files initial insider ownership report", "summary": "Virax Biolabs Group Ltd director Miller Iain David has filed a Form 3, an initial statement of beneficial ownership, with the SEC. This filing establishes his starting equity position as an insider of the company, confirming his role as a director. The Form 3 does not indicate an", "url": "https://www.stocktitan.net/sec-filings/VRAX/form-3-virax-biolabs-group-ltd-initial-statement-of-beneficial-owners-220e96388c62.html", "source_name": "Stock Titan", "published_at": "2026-03-19T14:38:52", "published_display": "19 Mar 2026 14:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPZ3ZESTUzR0F6Ti1LVHh6SElkcGZ5ZG5oclZ0MmJuUEZ1ZmhmVWlxbE5uZDc1cm5qbFE1T0ZVSm5UUmFRX0NpZ0Rvc0RGbWZ1Q3F4bEpFdHFzOEljclplUXNSdGNKcE5nRG54MmFPUUgwS3RxWGEwRWNBR1RGdS1oZHlDeW4?oc=5", "source_name": "Market source", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 50, "sentiment_summary": {"positive": 12, "negative": 6, "neutral": 32, "score": 55, "total": 50, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 16.5, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 3.85, "count": 9}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "macro", "label": "Macro sensitivity", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}], "positive_events": 12, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 4.08, "latest_week": "2026-07-10", "one_week_move": 30.4, "four_week_move": -11.3, "twelve_week_move": 8.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.726392, "market_dynamics_buy_signal": false, "relative_strength": -65.531793, "fair_value_gap": -87.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 40.2786, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+30.4% over one week, -11.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 13}, {"label": "Market source", "count": 8}, {"label": "TipRanks", "count": 5}, {"label": "PR Newswire", "count": 5}, {"label": "Sahm", "count": 4}, {"label": "The Globe and Mail", "count": 4}, {"label": "Quiver Quantitative", "count": 3}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 9}, {"label": "Deals and strategy", "count": 3}, {"label": "Macro sensitivity", "count": 3}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+30.4% over one week, -11.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "VRAX SEC Filings - Virax Biolabs Group Ltd 10-K, 10-Q, 8-K Forms"}], "updated_at": "2026-07-16T05:41:38.084073+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}